Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer

Early switching to de-intensified maintenance regimen is still a matter of debate in metastatic colorectal cancer (mCRC). The MARTHA trial, a S.I.C.O.G. phase III randomized trial, compared FOLOFIRI+bevacizumab (B) for 12 cycles (6 months) followed by B for up to 12 months (FOLFIRI +B*12 arm) vs FOL...

Descripción completa

Detalles Bibliográficos
Autores principales: Formica, Vincenzo, Ionta, Maria Teresa, Massidda, Bruno, Vessia, Giacomo, Maiorino, Luigi, Casaretti, Rossana, Natale, Donato, Barberis, Giuseppe, Filippelli, Gianfranco, Greco, Ettore, Blasi, Livio, Mancarella, Sergio, Russo, Anna, Barbato, Enrico, Lullo, Liberato Di, Roselli, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788688/
https://www.ncbi.nlm.nih.gov/pubmed/29416820
http://dx.doi.org/10.18632/oncotarget.23355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788688/
https://www.ncbi.nlm.nih.gov/pubmed/29416820
http://dx.doi.org/10.18632/oncotarget.23355

Ejemplares similares